Vertex Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex Pharma (VRTX) Sees Red-to-Green Reversal Following EPS
April 28, 2016 10:27 AM EDTVertex Pharma (NASDAQ: VRTX) reverse sharply off morning lows following earning after the close, which were seen as lackluster.
Shares are currently up 1% after opening down 3.9%.
... MoreVertex (VRTX) PT, Estimates Cut at Baird
April 28, 2016 7:45 AM EDTBaird analyst Brian Skorney lowered his price target on Vertex (NASDAQ: VRTX) to $128.00 (from $144.00) and Orkambi estimates on weak qua but maintained an Outperform rating.
Skorney commented, "Orkambi sales came in well below expectations that had already been revised significantly downwards over the last... More
Goldman Sachs Downgrades Vertex (VRTX) to Neutral
April 28, 2016 7:16 AM EDTGoldman Sachs downgraded Vertex (NASDAQ: VRTX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $84.50 yesterday.
... MoreVertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance
April 27, 2016 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.09, $0.20 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $398.1 million versus the consensus estimate of $439.36 million.
First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI® (lumacaftor/ivacaftor) and $171 million for KALYDECO®... More
